Neutropenia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Neutropenia – Pipeline Review, H2 2019’, provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Neutropenia

– The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects

– The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neutropenia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neutropenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acorn Biomedical Inc

Ahn-Gook Pharmaceutical Co Ltd

Apobiologix

Aprilbio Co Ltd

BeyondSpring Inc

Biocon Ltd

Biocure Technology Inc

Biosidus SA

Cellerant Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cleveland BioLabs Inc

CPL Biologicals Pvt Ltd

Dr. Reddy’s Laboratories Ltd

Genova Biotech Company Ltd

Kashiv BioSciences LLC

Ligand Pharmaceuticals Inc

Lupin Ltd

Merck & Co Inc

Mycenax Biotech Inc

Nexgen Biosciences

Phoenicia Biosciences Inc

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Siam Bioscience Co Ltd

Toko Pharmaceutical Industries Co Ltd

USV Pvt Ltd

X4 Pharmaceuticals Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Neutropenia Overview 6

Neutropenia Therapeutics Development 7

Neutropenia Therapeutics Assessment 14

Neutropenia Companies Involved in Therapeutics Development 22

Neutropenia Drug Profiles 33

Neutropenia Dormant Projects 102

Neutropenia Discontinued Products 104

Neutropenia Product Development Milestones 105

Appendix 113

List of Tables

“List of Tables

Number of Products under Development for Neutropenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Neutropenia – Pipeline by Acorn Biomedical Inc, H2 2019

Neutropenia – Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2019

Neutropenia – Pipeline by Apobiologix, H2 2019

Neutropenia – Pipeline by Aprilbio Co Ltd, H2 2019

Neutropenia – Pipeline by BeyondSpring Inc, H2 2019

Neutropenia – Pipeline by Biocon Ltd, H2 2019

Neutropenia – Pipeline by Biocure Technology Inc, H2 2019

Neutropenia – Pipeline by Biosidus SA, H2 2019

Neutropenia – Pipeline by Cellerant Therapeutics Inc, H2 2019

Neutropenia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Neutropenia – Pipeline by Cleveland BioLabs Inc, H2 2019

Neutropenia – Pipeline by CPL Biologicals Pvt Ltd, H2 2019

Neutropenia – Pipeline by Dr. Reddy’s Laboratories Ltd, H2 2019

Neutropenia – Pipeline by Genova Biotech Company Ltd, H2 2019

Neutropenia – Pipeline by Kashiv BioSciences LLC, H2 2019

Neutropenia – Pipeline by Ligand Pharmaceuticals Inc, H2 2019

Neutropenia – Pipeline by Lupin Ltd, H2 2019

Neutropenia – Pipeline by Merck & Co Inc, H2 2019

Neutropenia – Pipeline by Mycenax Biotech Inc, H2 2019

Neutropenia – Pipeline by Nexgen Biosciences, H2 2019

Neutropenia – Pipeline by Phoenicia Biosciences Inc, H2 2019

Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, H2 2019

Neutropenia – Pipeline by Richter Gedeon Nyrt, H2 2019

Neutropenia – Pipeline by Siam Bioscience Co Ltd, H2 2019

Neutropenia – Pipeline by Toko Pharmaceutical Industries Co Ltd, H2 2019

Neutropenia – Pipeline by USV Pvt Ltd, H2 2019

Neutropenia – Pipeline by X4 Pharmaceuticals Inc, H2 2019

Neutropenia – Dormant Projects, H2 2019

Neutropenia – Dormant Projects, H2 2019 (Contd..1), H2 2019

Neutropenia – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Neutropenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports